COVID-19 Therapy Market Overview: Major Segments, Strategic Developments, and Leading Companies

The landscape of COVID-19 treatment is evolving rapidly as the world adjusts to new healthcare realities. While the market for current COVID-19 therapies is shifting, understanding its projected changes, key players, and emerging trends provides valuable insight into how treatment strategies and innovations will shape the future.

Projected Market Changes in the COVID-19 Current Therapy Sector
The COVID-19 current therapy market is predicted to experience a sharp downturn over the coming years. Forecasts indicate the market size will shrink to $0.31 billion by 2030, reflecting a compound annual growth rate (CAGR) of -33.2%. This significant decline is largely due to reduced telemedicine use for COVID-19 management and slower growth in home care services. Despite this decrease, certain trends continue to influence the market, including increased adoption of antiviral and monoclonal antibody treatments, a rise in corticosteroid usage for severe cases, expansion in home care and remote patient monitoring, growing interest in supplements and immune support therapies, and the incorporation of combination and experimental therapies in treatment protocols.

Download a free sample of the covid-19 current therapy market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3247&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Top Companies Leading the COVID-19 Current Therapy Market
Several key organizations dominate the COVID-19 therapy space. These include Gilead Sciences Inc., Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals Inc., Canary Health Technologies, and Thermo Fisher Scientific. A notable strategic move in this market occurred in July 2024, when CureVac N.V., a biotechnology firm based in the Netherlands, teamed up with UK-based GlaxoSmithKline plc (GSK) to restructure their mRNA vaccine collaboration into a licensing agreement. This partnership aims to enhance vaccine development and commercialization, leveraging CureVac's mRNA platform alongside GSK's expansive regulatory, manufacturing, and commercial expertise to accelerate vaccine availability and broaden global reach.

Emerging Trends Highlighting Opportunities in COVID-19 Therapy
Leading companies in the COVID-19 current therapy market are prioritizing innovation to maintain competitiveness. A significant focus is on developing oral antiviral treatments designed to inhibit virus replication effectively. For example, in April 2024, US-based Invivyd launched PEMGARDATM, an antibody-based therapy granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA). This treatment targets individuals with moderate-to-severe immune compromise to prevent COVID-19 infection, representing a critical advancement in protecting vulnerable populations.

View the full covid-19 current therapy market report:
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Market Segmentation and Dominant Categories in COVID-19 Current Therapy
The COVID-19 current therapy market is categorized into key segments:
1) By Drug Type: including antivirals, monoclonal antibodies, corticosteroids, supplements, antimalarials, interferons and interleukin inhibitors, and other anti-infective drugs.
2) By Route of Administration: oral and intravenous.
3) By End-User: hospitals, clinics, home care, and others.

Further detailed subsegments include specific antiviral drugs such as Remdesivir, Oseltamivir, Favipiravir, and Nirmatrelvir or ritonavir (Paxlovid); monoclonal antibodies like Bamlanivimab, Casirivimab or Imdevimab (REGEN-COV), Sotrovimab, and Etesevimab; corticosteroids such as Dexamethasone, Hydrocortisone, and Prednisone; supplements including Vitamin D, Vitamin C, Zinc, and Quercetin; antimalarial drugs like Hydroxychloroquine and Chloroquine; interferons and interleukin inhibitors such as Interferon beta-1a and Interleukin-6 inhibitors; plus other anti-infective medications like antibiotics and antifungal agents.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.